Skip to content
lifestyle.streetregister.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tenaya Therapeutics, Inc.
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
September 14, 2026
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
September 3, 2026
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 4, 2026
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 14, 2026
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
June 29, 2026
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
June 3, 2026
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
June 2, 2026
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
May 29, 2026
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
May 24, 2026
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 23, 2026
1
2
Next Page
→